Why Did 10x Genomics (TXG) Stock Climb Today?
The Fred Hutchinson Cancer Center collaboration gives 10x Genomics (TXG) its first clinical research push into blood cancers, extending single cell and spatial work in solid tumors into hematologic malignancies with a clear diagnostic focus.
For context, 10x Genomics has seen very strong recent momentum, with a 30 day share price return of 19.85% and a 90 day move of 88.74%. The 1 year total shareholder return is very large at about 7x, while the 5 year total shareholder return shows a decline of 47.03%. This latest 4.36% one day share price gain to US$80.65, coming after the Fred Hutch alliance and recent Atera and Sentira product updates, indicates that investors are currently reacting to both the clinical oncology push and the expanding spatial and cloud analysis product suite as they reassess growth potential and risk.
Scan beyond 10x Genomics to see how other precision oncology and advanced biology players stack up, using our hand picked 34 healthcare AI stocks as a starting point.
10x Genomics now trades above the average analyst target and at a steep premium to many traditional valuation gauges. After a 7x one year total return, is this caution from the market, or restraint from analysts that looks more reasonable?
Most Popular Narrative: 30% Overvalued
On the most followed narrative, 10x Genomics screens as expensive, with a fair value of $62.13 against the latest close at $80.65, which pushes the focus onto what needs to go right for that gap to close.
Recent and upcoming product launches, including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein, are expanding the range of applications and reinforcing 10x''s leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.
See why 27 investors see 10x Genomics as 30% overvalued.
Result: Fair Value of $62.13 (OVERVALUED)
Still, shrinking pricing power on core instruments and the ongoing net loss of US$75.1 million leave 10x Genomics exposed if funding or product transitions disappoint.
Find out about the key risks to this 10x Genomics narrative.
Next Steps
If this mixed read on 10x Genomics leaves you torn, act while the data is fresh and weigh both sides for yourself using our breakdown of 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond 10x Genomics?
Do not stop with 10x Genomics alone. Broaden your watchlist now so you have real options ready when the next setup appears.
- Target potential mispricing by checking stocks that score well on quality and valuation filters through our 28 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies with robust yields and payout profiles using our focused 8 dividend fortresses.
- Sleep easier at night by scanning for resilient businesses that carry lower overall risk signals with the help of our 31 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com